K
Kei Matsueda
Researcher at University of Chicago
Publications - 44
Citations - 1458
Kei Matsueda is an academic researcher from University of Chicago. The author has contributed to research in topics: Acotiamide & Irritable bowel syndrome. The author has an hindex of 15, co-authored 44 publications receiving 1387 citations.
Papers
More filters
Journal ArticleDOI
Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan.
TL;DR: It is suggested that increased dietary intake of animal protein and n-6 polyunsaturated fatty acids with less n-3 polyuns saturated fatty acids may contribute to the development of Crohn disease.
Journal ArticleDOI
Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study.
Takashi Shimoyama,Koji Sawada,Nobuo Hiwatashi,Toshio Sawada,Kei Matsueda,Akihiro Munakata,Hitoshi Asakura,Takao Tanaka,Reiji Kasukawa,Ken Kimura,Yasuo Suzuki,Yukio Nagamachi,Tetsuichiro Muto,Hirokazu Nagawa,Bunei Iizuka,Shozo Baba,Masaru Nasu,Tatsuji Kataoka,Nobuhito Kashiwagi,Abby R. Saniabadi +19 more
TL;DR: Based on the results, it is believed that in patients with active severe UC, patients who are refractory to conventional drugs, granulocyte and monocyte adsorption apheresis is a useful adjunct to conventional therapy.
Journal ArticleDOI
Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits.
TL;DR: The mucosal 5-HT concentrations in the colon showed an ascending cephalocaudal gradient in all study groups and further studies are necessary to determine whether the elevated mucosal5-HT is a cause or a result of abnormal colonic motility.
Journal ArticleDOI
A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome.
TL;DR: Ramosetron hydrochloride 5 µg once daily is effective and well tolerated in the treatment of abdominal pain, discomfort and bowel habits in patients with diarrhea-predominant irritable bowel syndrome.
Journal ArticleDOI
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
TL;DR: Ramosetron is an effective and well-tolerated treatment not only for female IBS patients but also for male patients and there was tolerability at doses up to 10 µg.